abacavir
Antiinfectives for systemic use (J05)US regulatory status: approved.
pharma · HIV Infections · Infection, Human Immunodeficiency Virus
ViiV Healthcare
ViiV Healthcare B.V.
ViiV Healthcare drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
London, GB HQ
2009 Founded
1,906 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- London, GB
- Founded
- 2009
- Employees
- 1,906
- Programs
- 3
- Drugs
- 5
- Patents
- 0
ViiV Healthcare pipeline
Portfolio lens on 5 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
ViiV Healthcare drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to ViiV Healthcare in public FDA and regional records.
-
dolutegravir
Antiinfectives for systemic use (J05)US regulatory status: approved.
-
Development asset linked to ViiV Healthcare in public FDA and regional records.
-
lamivudine
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor